Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
Media Release COPENHAGEN, Denmark; October 18, 2025 Updated data from the Phase…
ITM Announces Phase 3 COMPETE Data Demonstrating a Statistically Significant Higher Objective Response Rate with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus in Patients with Gastroenteropancreatic Neuroendocrine Tumors at ESMO 2025
Study data also showed prolonged progression-free survival with 177Lu-edotreotide compared to everolimus…
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving…
Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025
October 17, 2025 16:05 ET | Source: Jade Biosciences Presentations to highlight…
Fagrons share buy-back program: Weekly update
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 17 October 2025 – 6PM CET Fagron’s…
Junshi Biosciences Announces FDAs Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients
SHANGHAI, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd…
The Hemp Doctor Debuts 6.5G THC Disposable Vape: Bolder & Stronger Than Ever
MOORESVILLE, N.C., Oct. 16, 2025 (GLOBE NEWSWIRE) -- The Hemp Doctor, a…
Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner’s National Priority Voucher Pilot Program
REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc.…
Roche presents major advances for its sequencing by expansion technology(1), including a new GUINNESS WORLD RECORD, at the ASHG conference 2025
Significant progress in bulk RNA sequencing, methylation mapping, multiomics integration, and spatial…
